Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Common Nutritional Supplement Shows Surprising Promise Against Psoriasis (opens in a new tab)

scitechdaily.com · 2026-11-04

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of five claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 3 supported
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredThe findings were supported by experiments in mice and a small clinical trial involving 24 psoriasis patients over 12 weeks; half received pantethine in addition to topical calcipotriene/betamethasone, and the supplement group improved, especially among patients with elevated blood cholesterol.View evidenceHide evidence

As stated24 patients; 12 weeks; half of participants received pantethine

Why this verdict

The profile supports the broad existence of mouse experiments and an investigator-initiated psoriasis trial of pantethine combination therapy reporting symptom relief. However, at abstract depth it does not provide the stated trial details: 24 patients, 12 weeks, half receiving pantethine, use with topical calcipotriene/betamethasone, or stronger improvement among patients with elevated cholesterol.

1

Study evidence

Pantethine supplementation reduced membrane cholesterol accumulation, impeded dendritic cell activation, and mitigated psoriasiform inflammation in mice.

“Pantethine supplementation or pharmacologically induced Vanin inhibition reduces cholesterol overload, impedes DC activation, and mitigates psoriasiform inflammation.”
2

Study evidence

Investigator-initiated clinical trial reported that pantethine combination therapy relieved clinical symptoms in psoriasis patients.

“our investigator-initiated trial shows that pantethine combination therapy relieves clinical symptoms in psoriasis patients.”
Claim 2 of 5Not coveredThe researchers reported unusually high Vanin enzyme levels in dendritic cells from patients with psoriasis and other autoimmune conditions, and proposed a Vanin-pantethine-cholesterol pathway that drives dendritic-cell activation and inflammation.View evidenceHide evidence

Why this verdict

The profile supports Vanin upregulation in activated dendritic cells from autoimmune patients and supports a Vanin–pantethine–cholesterol mechanism promoting dendritic-cell hyperactivation and psoriasiform inflammation in experimental systems. But the abstract-level profile does not verify the more specific wording that levels were unusually high in dendritic cells from psoriasis patients specifically, does not provide disease-specific human breakdowns, and does not verify the quoted statement about insufficient pantethine levels being a crucial contributor.

1

Study evidence

Vanin is upregulated in activated dendritic cells from autoimmune patients (human-derived DC specimens assayed in the study).

“Vanin is upregulated in activated DCs from autoimmune patients”
2

Study evidence

DC-specific Vanin deficiency significantly alleviates psoriasiform inflammation in mice.significant reduction in disease severity (not quantified in abstract)

“DC-specific Vanin deficiency significantly alleviates psoriasiform inflammation in mice.”
Claim 3 of 5SupportedPantethine, a derivative of vitamin B5 and a widely available nutritional supplement, showed unexpected promise for treating psoriasis.View evidenceHide evidence

Why this verdict

The paper profile supports an early-promise framing: pantethine supplementation mitigated psoriasiform inflammation in mice, and an investigator-initiated human trial reported symptom relief with pantethine combination therapy. The headline wording is hedged as 'promise' rather than proven treatment, so it does not outrun the body’s caveats. The supplied abstract-level profile does not independently verify the background descriptor that pantethine is a widely available vitamin B5-derived supplement.

1

Study evidence

Pantethine supplementation reduced membrane cholesterol accumulation, impeded dendritic cell activation, and mitigated psoriasiform inflammation in mice.

“Pantethine supplementation or pharmacologically induced Vanin inhibition reduces cholesterol overload, impedes DC activation, and mitigates psoriasiform inflammation.”
2

Study evidence

Investigator-initiated clinical trial reported that pantethine combination therapy relieved clinical symptoms in psoriasis patients.

“our investigator-initiated trial shows that pantethine combination therapy relieves clinical symptoms in psoriasis patients.”
Claim 4 of 5SupportedNew research from China found that pantethine may help reduce the immune system activity responsible for psoriasis by interfering with metabolic processes that drive inflammation.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the mechanistic claim that pantethine/Vanin-axis modulation can reduce dendritic-cell activation through cholesterol/lipid-raft metabolic effects. The story’s 'may help' wording is appropriately hedged, although the direct clinical mechanism in patients is not established by the abstracted trial evidence.

1

Study evidence

Vanin hydrolyzes pantethine as reported in the abstract.

“Mechanistically, Vanin hydrolyzes pantethine, leading to cholesterol and lipid raft accumulation on the cell membrane and promoting DC hyperactivation.”
2

Study evidence

Pantethine supplementation reduced membrane cholesterol accumulation, impeded dendritic cell activation, and mitigated psoriasiform inflammation in mice.

“Pantethine supplementation or pharmacologically induced Vanin inhibition reduces cholesterol overload, impedes DC activation, and mitigates psoriasiform inflammation.”
Claim 5 of 5SupportedThe article says the results are preliminary and do not establish pantethine as an effective standalone treatment.View evidenceHide evidence

Why this verdict

The paper profile describes the human evidence as pantethine combination therapy, not standalone pantethine treatment, and the abstract lacks key trial-design and quantitative outcome details. The story’s caveat that the results are preliminary and do not establish pantethine as an effective standalone treatment is therefore consistent with the supplied evidence.

1

Study evidence

Investigator-initiated clinical trial reported that pantethine combination therapy relieved clinical symptoms in psoriasis patients.

“our investigator-initiated trial shows that pantethine combination therapy relieves clinical symptoms in psoriasis patients.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • DC-specific Vanin deficiency significantly alleviates psoriasiform inflammation in mice, supporting a DC-intrinsic causal role for Vanin.

    The story mentions mouse experiments generally and pantethine effects, but it does not specifically report the central genetic loss-of-function evidence that DC-specific Vanin deficiency alleviated psoriasiform inflammation.

    From DC-specific Vanin deficiency in mouse psoriasiform inflammation model

  • Pharmacologic Vanin inhibition with RR6 also reduced dendritic-cell activation and mitigated psoriasiform inflammation.

    The story focuses on pantethine and does not materially cover the parallel Vanin-inhibitor/RR6 intervention reported in the paper profile.

    From in_vivo_animal_treatment; ex vivo human DC activation assays

  • Ex vivo treatment of patient-derived dendritic cells with pantethine or RR6 impaired dendritic-cell activation.

    The story discusses a proposed mechanism and a clinical trial, but it does not clearly report the separate human specimen-based ex vivo dendritic-cell activation assays.

    From ex vivo human DC activation assays

  • The human trial evidence is limited at abstract depth: the profile lacks design details, randomization/blinding/comparator information, numerical outcomes, statistical results, and safety data.

    The story does mention that the trial was small, preliminary, not standalone, and not a direct validation of the mechanism. However, it does not reflect several interpretation-changing limitations present in the abstract profile, especially the absence of trial design details, quantitative outcomes, statistical support, and safety/adverse-event reporting.

    From Investigator-initiated clinical trial (human in vivo intervention)

5 things the story did carry across
  • Vanin is upregulated in activated dendritic cells from autoimmune patients and mice.
  • Mechanism: Vanin hydrolyzes pantethine, leading to cholesterol and lipid-raft accumulation and promoting dendritic-cell hyperactivation.
  • Pantethine supplementation mitigated psoriasiform inflammation and reduced dendritic-cell activation in mouse models.
  • Investigator-initiated clinical trial: pantethine combination therapy relieved clinical symptoms in psoriasis patients.
  • Animal and ex vivo mechanistic findings do not by themselves establish clinical efficacy in humans.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

7

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalDC-intrinsic Vanin promotes psoriasiform inflammation in vivo; DC-specific Vanin deficiency alleviates disease in mice.DC-specific Vanin deficiency in mouse psoriasiform inflammation modelExpand

In plain English

In a mouse psoriasiform inflammation model, conditional DC-specific Vanin deficiency reduced disease severity, indicating a DC-intrinsic role for Vanin in promoting psoriasiform inflammation. The abstract reports this genetic perturbation (DC-specific Vanin loss) as linked to alleviation of clinical and histologic measures of psoriasiform inflammation and immune phenotypes.

Key findings

  • DC-specific Vanin deficiency significantly alleviates psoriasiform inflammation in mice.significant reduction in disease severity (not quantified in abstract)
“DC-specific Vanin deficiency significantly alleviates psoriasiform inflammation in mice.”
What this piece can’t prove
  • The reported result is from a mouse psoriasiform model; the abstract suggests human relevance elsewhere but this unit addresses only the mouse DC-specific deficiency experiment.

2 further details could not be confirmed from the summary.

2ex vivo humanVanin is upregulated in activated dendritic cells in autoimmune disease (humans and mice), implicating Vanin in DC activation associated with inflammatory disorders.ex vivo humanExpand

In plain English

The paper's abstract reports that Vanin expression is increased in activated dendritic cells (DCs) from autoimmune patients based on assays of patient-derived DC specimens; specific numerical effect sizes and detailed methods are not provided in the abstract.

Key findings

  • Vanin is upregulated in activated dendritic cells from autoimmune patients (human-derived DC specimens assayed in the study).
“Vanin is upregulated in activated DCs from autoimmune patients”
What this piece can’t prove
  • Lack of assay-specific methodological detail (platform, markers, normalization) prevents assessment of measurement robustness.
  • Ambiguity about whether activation state was measured directly ex vivo or after experimental activation.

2 further details could not be confirmed from the summary.

3in vivo animalVanin is upregulated in activated dendritic cells in autoimmune disease (humans and mice), implicating Vanin in DC activation associated with inflammatory disorders.in vivo animalExpand

In plain English

Abstract-level report that Vanin expression is increased in activated dendritic cells in mouse inflammatory/autoimmune models; this unit focuses on the observation of Vanin upregulation in activated mouse DCs assessed by isolating DCs from in vivo models and comparing activated versus baseline cells.

Key findings

  • Vanin is upregulated in activated dendritic cells in mouse models of inflammation/autoimmunity.
“Vanin is upregulated in activated DCs from autoimmune patients and mice”
What this piece can’t prove
  • Summary is based solely on the abstract statement; full experimental details are not available.
  • No quantitative effect sizes, sample sizes, variance measures, or statistical test results are reported in the provided text.

1 further detail could not be confirmed from the summary.

4in vitroMechanism: Vanin hydrolyzes pantethine, driving cholesterol accumulation/lipid raft remodeling that promotes DC hyperactivation (Vanin–pantethine–cholesterol axis).in vitro DC mechanistic assaysExpand

In plain English

The abstract reports mechanistic in vitro findings that Vanin enzymatic activity hydrolyzes pantethine in dendritic cells, which the authors link to increased membrane cholesterol and lipid-raft accumulation and consequent DC hyperactivation. Perturbing the axis (pantethine supplementation or pharmacologic Vanin inhibition) is reported to reduce cholesterol overload and impede DC activation.

Key findings

  • Vanin hydrolyzes pantethine as reported in the abstract.
  • Vanin activity is linked to increased membrane cholesterol and lipid-raft accumulation in dendritic cells.
“Mechanistically, Vanin hydrolyzes pantethine, leading to cholesterol and lipid raft accumulation on the cell membrane and promoting DC hyperactivation.”
What this piece can’t prove
  • Summary is based solely on the abstract; full experimental details (methods, sample sizes, controls, statistical analyses) are not available here.
  • The abstract does not specify whether enzymatic pantethine hydrolysis was demonstrated biochemically in purified systems or inferred from cellular metabolite changes.

1 further detail could not be confirmed from the summary.

5in vivo animalTherapeutic targeting: pantethine supplementation and/or pharmacologic Vanin inhibition reduces DC activation and mitigates psoriasiform inflammation; includes human patient-derived DC assays and an investigator-initiated clinical trial in psoriasis.in vivo animal treatmentExpand

In plain English

In mouse psoriasiform inflammation models, in vivo administration of pantethine or pharmacologic Vanin inhibition (RR6) reduced membrane cholesterol accumulation, impeded dendritic cell (DC) activation, and mitigated psoriasiform disease severity.

Key findings

  • Pantethine supplementation reduced membrane cholesterol accumulation, impeded dendritic cell activation, and mitigated psoriasiform inflammation in mice.
  • Pharmacologic inhibition of Vanin (RR6) reduced dendritic cell activation and mitigated psoriasiform inflammation in mice.
“Pantethine supplementation or pharmacologically induced Vanin inhibition reduces cholesterol overload, impedes DC activation, and mitigates psoriasiform inflammation.”
What this piece can’t prove
  • Findings derive from an animal disease model; translational relevance to human disease requires direct evidence not contained in this unit's scope.

2 further details could not be confirmed from the summary.

6ex vivo humanTherapeutic targeting: pantethine supplementation and/or pharmacologic Vanin inhibition reduces DC activation and mitigates psoriasiform inflammation; includes human patient-derived DC assays and an investigator-initiated clinical trial in psoriasis.ex vivo human DC activation assaysExpand

In plain English

Ex vivo treatment of patient-derived dendritic cells with pantethine or the Vanin inhibitor RR6 reduced DC activation measured by activation markers and cytokine readouts.

Key findings

  • Pantethine or RR6 treatment impairs activation of patient-derived dendritic cells in ex vivo assays.
“pantethine or RR6 treatment impairs activation of patient-derived DCs”
What this piece can’t prove
  • Ex vivo modulation of DCs may not capture in vivo pharmacodynamics, dosing, or systemic effects.

2 further details could not be confirmed from the summary.

7human in vivoTherapeutic targeting: pantethine supplementation and/or pharmacologic Vanin inhibition reduces DC activation and mitigates psoriasiform inflammation; includes human patient-derived DC assays and an investigator-initiated clinical trial in psoriasis.Investigator-initiated clinical trial (human in vivo intervention)Expand

In plain English

An investigator-initiated clinical trial reported that pantethine combination therapy relieved clinical symptoms in psoriasis patients. The abstract provides no trial design details, numerical outcomes, or safety data.

Key findings

  • Investigator-initiated clinical trial reported that pantethine combination therapy relieved clinical symptoms in psoriasis patients.
“our investigator-initiated trial shows that pantethine combination therapy relieves clinical symptoms in psoriasis patients.”
What this piece can’t prove
  • Key trial design elements (randomization, comparator, blinding) are unspecified, limiting evaluation of internal validity.
  • No information on sample size, baseline characteristics, outcome measures, effect sizes, or statistical significance is provided.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 36 candidate papers

Candidate

TEACHER-REVIEWED GENERATIVE AI LESSON PLANNING: A QUASI-EXPERIMENTAL ANALYSIS OF PERCEIVED PEDAGOGICAL QUALITY | EDUCATIONAL RESEARCH AND INNOVATION

Scholarly Journal · 2026 · Crossref

Source (opens in a new tab)

And 30 more candidates considered.